Ardian France’s acquisition of Equistone Partners majority stake in Unither Pharmaceuticals Group

Paul Hastings has advised Equistone Partners Europe in connection with the sale of its majority stake in Unither Pharmaceuticals Group to the investment company Ardian France.

Unither Pharmaceuticals group is the world leader of pharmaceutical subcontracting and specializes in the manufacture of sterile single doses, various containers and generic drugs for the pharmaceutical industry. Established in France, the United States and Brazil, the Group employs nearly 1,200 people. It has a turnover of 250 million euros.

Completion is subject to the approval of the regulatory and competition authorities, as well as that of the Unither Pharmaceuticals group employees’ representatives.

The Paul Hastings team was composed of partners Olivier Deren (Picture) and Sébastien Crepy and associate Valentin Savage for corporate and contractual aspects, and partner Allard de Waal and associate Thomas Pulcini for tax aspects.

Unither Pharmaceuticals group and the management team of Unither Pharmaceuticals were advised by Lamartine Conseil with Olivier Renault and Fabien Mauvais.

Ardian France was advised by DLA Piper with Xavier Norlain and Bertrand Levy.

Involved fees earner: Olivier Renault – Lamartine Conseil; Fabien Mauvais – Lamartine Conseil; Olivier Deren – Paul Hastings; Sébastien Crépy – Paul Hastings; Valentin Savage – Paul Hastings; Allard de Waal – Paul Hastings; Thomas Pulcini – Paul Hastings; Xavier Norlain – DLA Piper; Bertrand Lévy – DLA Piper;

Law Firms: Lamartine Conseil; Paul Hastings; DLA Piper;

Clients: Equistone Partners Europe; Ardian; Unither Pharmaceuticals Group; Eric Goupil; Patrick Colin;

Print Friendly, PDF & Email